 Connection
Hanmant Gaikwad to Doxorubicin
This is a "connection" page, showing publications Hanmant Gaikwad has written about Doxorubicin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.373 |
|
|
|
-
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi SM, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Mol Pharm. 2024 06 03; 21(6):3053-3060.
Score: 0.175
-
Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D. PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities via Passive Extravasation across "Leaky" Endothelium. ACS Nano. 2022 Apr 26; 16(4):6349-6358.
Score: 0.151
-
Li Y, Jacques S, Gaikwad H, Nebbia M, Banda NK, Holers VM, Tomlinson SA, Scheinman RI, Monte A, Saba L, Lasda E, Hasselberth J, Busquet N, Zelek WM, Moghimi SM, Simberg D. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Sci Adv. 2025 Jul 11; 11(28):eadw1731.
Score: 0.047
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|